|
IL-2
|
IL-6
|
IL-10
|
IL-12
|
IFN- γ
|
TNF
|
IP-10
|
G-CSF
|
---|
VIR25
|
P. vivax
|
10
|
27
|
34
|
42
|
14
|
62
|
10
|
98
|
Healthy control
|
13
|
19
|
31
|
46
|
11
|
56
|
12
|
102
|
P values
|
0.225
|
0.092
|
0.103
|
0.312
|
0.098
|
0.236
|
0.168
|
0.263
|
VIR-C2
|
P. vivax
|
89**
|
41*
|
102*
|
74*
|
13
|
112*
|
12
|
195*
|
Healthy control
|
11
|
20
|
33
|
42
|
12
|
64
|
9
|
112
|
P values
|
< 0.001
|
0.029
|
0.018
|
0.035
|
0.156
|
0.031
|
0.264
|
0.039
|
PvLP1
|
P. vivax
|
7
|
29
|
52
|
40
|
11
|
72
|
13
|
124
|
Healthy control
|
10
|
12
|
39
|
41
|
12
|
69
|
10
|
96
|
P values
|
0.265
|
0.314
|
0.247
|
0.184
|
0.206
|
0.105
|
0.241
|
0.198
|
PvLP2
|
P. vivax
|
32*
|
72*
|
132**
|
61
|
13
|
103*
|
13
|
159*
|
Healthy control
|
12
|
19
|
49
|
49
|
11
|
64
|
15
|
95
|
P values
|
0.045
|
0.013
|
< 0.001
|
0.235
|
0.153
|
0.031
|
0.128
|
0.015
|
PvMSP1-19
|
P. vivax
|
125**
|
95**
|
89**
|
58
|
15
|
120*
|
49
|
201*
|
Healthy control
|
16
|
14
|
39
|
46
|
13
|
62
|
45
|
106
|
P values
|
< 0.001
|
< 0.001
|
< 0.001
|
0.391
|
0.153
|
0.013
|
0.364
|
0.041
|
GST
|
P. vivax
|
10
|
25
|
38
|
51
|
14
|
67
|
10
|
116
|
Healthy control
|
12
|
16
|
31
|
41
|
12
|
62
|
11
|
102
|
P values
|
0.125
|
0.312
|
0.186
|
0.216
|
0.234
|
0.163
|
0.113
|
0.265
|
Medium
|
P. vivax
|
10
|
39
|
35
|
50
|
13
|
70
|
10
|
121
|
Healthy control
|
16
|
15
|
32
|
45
|
15
|
68
|
9
|
110
|
P values
|
0.315
|
0.132
|
0.327
|
0.192
|
0.264
|
0.162
|
0.298
|
0.225
|
- n = 25 for P. vivax-infected groups; n = 30 for healthy control
- *P < 0.05 for P. vivax-infected patients versus control individuals
- **P < 0.001 for P. vivax-infected patients versus control individuals